APA (7th ed.) Citation

Albrecht, L. J., Dimitriou, F., Grover, P., Hassel, J. C., Erdmann, M., Forschner, A., . . . Zimmer, L. (2024). Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma. European journal of cancer, 202, . https://doi.org/10.1016/j.ejca.2024.113976

Chicago Style (17th ed.) Citation

Albrecht, Lea Jessica, et al. "Anti-PD-(L)1 Plus BRAF/MEK Inhibitors (triplet Therapy) After Failure of Immune Checkpoint Inhibition and Targeted Therapy in Patients with Advanced Melanoma." European Journal of Cancer 202 (2024). https://doi.org/10.1016/j.ejca.2024.113976.

MLA (9th ed.) Citation

Albrecht, Lea Jessica, et al. "Anti-PD-(L)1 Plus BRAF/MEK Inhibitors (triplet Therapy) After Failure of Immune Checkpoint Inhibition and Targeted Therapy in Patients with Advanced Melanoma." European Journal of Cancer, vol. 202, 2024, https://doi.org/10.1016/j.ejca.2024.113976.